GAITHERSBURG, Maryland., November 14, 2023 /PRNewswire/ — YS Biopharma Co., Ltd. (NASDAQ: Yes) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, manufacturing and supply of new generations of vaccines and therapeutic biologics against infectious diseases and cancer, is pleased to announce that Noble Capital Markets (“Noble”) has initiated research on the company’s stock with an “Outperform” rating and a 12-month price target of US$5.25 per share. The full report from Noble Capital Markets, Senior Healthcare Services and Medical Devices Analyst Grégory Aurandas well as news and advanced market data on YS Biopharma, are available at Channel control. The report is also available through the Company’s Investor Relations website. here.
Highlights of the report include:
- PIKA immunomodulatory platform. New PIKA technology has the ability to target and accelerate the immune response in a wide variety of vaccines and immuno-oncology treatments. PIKA activates and improves the body’s immune response, thereby increasing the effectiveness of vaccines. In immuno-oncology, with its multiple modes of action capable of inducing the production of multiple tumor-inhibiting cytokines and apoptosis of tumor cells, PIKA could be applied to broad-spectrum anti-tumor activity in cancers.
- Significant opportunities in the antiviral and immuno-oncology markets. There are significant unmet needs in Africa, South East Asia And China, among other regions of the world, in rabies, hepatitis B and cancers. THE Asia Pacific The region is expected to experience the highest growth rate in the world, with higher levels of use of immunotherapies, driven by low vaccine penetration, increasing cancer prevalence and improving patient awareness and disposable income .
- Marketed anti-rabies vaccine. Currently, YS Biopharma markets YSJA rabies virus vaccine, the first aluminum-free freeze-dried rabies vaccine launched in China. The YSJA vaccine, a more traditional vaccine, is more effective and has a better safety profile than other vaccines and has achieved approximately 11% market share since its launch in 2020, although the pandemic during the calendar year 2023 has had a negative effect on the supply chain and production yield. The YSJA vaccine not only helps support the construction of commercial infrastructure, but also supports PIKA’s research and development pipeline.
- Initiate with outperformance. The noble ones $5.25 1-year price target is based on FY2029 EPS 6.93 RMB ($0.95), discounted at 30% and applying a Nasdaq earnings multiple of 20x. The multiple reflects an average Nasdaq price-to-earnings ratio which Noble says reflects the growth opportunity. For a smaller company with less certain cash flow and development and product risks, Noble assigns a higher discount rate.
Any reports on YS Biopharma prepared by analysts represent the opinions of those analysts and are not necessarily those of the Company. YS Biopharma is not responsible for the content, accuracy or timeliness provided by analysts. YS Biopharma does not expressly or implicitly guarantee or assume any legal responsibility for the accuracy, completeness or usefulness of any information, assumptions, data, forecasts, price targets, estimates or projections contained in the reports or notes industry reports provided by analysts, and the dissemination of such reports or industry notes does not necessarily constitute or imply endorsement or recommendation by YS Biopharma. The Company participates in Noble Capital Markets’ Company Sponsored Research Program (“CSRP”) and Noble Capital Markets receives compensation from the Company for this participation. No part of CSRP’s compensation was, is or will be directly or indirectly related to any specific recommendations or opinions expressed by the analyst in this research report.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to the discovery, development, manufacturing and delivery of new generations of vaccines and therapeutic biologics against infectious diseases and cancer. He developed a proprietary PIKA® immunomodulatory technology platform and a new generation of preventive and therapeutic biologics targeting rabies, coronavirus, hepatitis B, influenza, shingles and other viral infections. YS Biopharma is present in China, the United States, Singapore and the United States. Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharm.com.
About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC/FINRA-registered broker-dealer dedicated exclusively to serving under-followed small and micro-cap companies through investment banking, wealth management, trading and execution and equity research. Over the past 37 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. For more information, please visit www.noblecapitalmarkets.comor email (email protected).
Channelchek (.com) is a comprehensive investor-centric portal – featuring over 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive interviews with top executives and access to virtual roadshows. The site is accessible to the public at all levels without cost or commitment. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC/FINRA registered broker-dealer since 1984. For more information, please visit www.channelchek.comor email (email protected).
Caution Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including, but not limited to, statements regarding YS Biopharma’s expected growth, development progress of all product candidates, progress and results of all clinical studies. trials, YS Biopharma’s ability to source and retain talent, and YS Biopharma’s cash position following the closing of the business combination. Forward-looking statements can be identified by the use of words such as “estimate”, “plan”, “project”, “forecast”, “intend”, “intend”, “expect”, “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or are not statements. historical questions. These statements are based on various assumptions, whether identified in this press release, and the current expectations of YS Biopharma’s management and are not predictions of actual performance.
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Although YS Biopharma believes it has a reasonable basis for each forward-looking statement contained in this press release, YS Biopharma cautions you that such statements are based on a combination of currently known facts and factors and future projections, which are inherently uncertain. . In addition, there are risks and uncertainties described in the final prospectus relating to the proposed business combination and other documents filed by YS Biopharma from time to time with the SEC. These documents may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
YS Biopharma cannot assure you that the forward-looking statements contained in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to recognize the anticipated benefits of the business combination, the costs associated with the transaction, the impact of the global pandemic of COVID-19, the risk that the transaction disrupts current plans and operations due to the consummation of the transaction, the outcome of any potential litigation, any governmental or regulatory proceedings, the commercial performance of the marketed vaccine product and clinical trial development results of YS Biopharma’s product candidates, as well as other risks and uncertainties, including those included in YS Biopharma’s filings with the SEC. There may be additional risks not currently known to YS Biopharma or that YS Biopharma currently believes to be immaterial, which could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties relating to these forward-looking statements, nothing in this press release should be construed as a representation by any person that the forward-looking statements set forth herein will be realized or that any of the contemplated results of such forward-looking statements – interesting statements will be obtained. The forward-looking statements contained in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may change these views. However, although YS Biopharma may update these forward-looking statements in the future, there is currently no intention to do so, except as required by applicable law. You should therefore not rely on these forward-looking statements as representing the views of YS Biopharma as of any date after the date of this press release. Except as required by law, YS Biopharma undertakes no obligation to update these forward-looking statements.
Investor Relations Contacts
Director of Investor Relations
E-mail: (email protected)
Partner, ICR, LLC
Tel: +1 (212) 537-4035
E-mail: (email protected)
SOURCE YS Biopharma Co., Ltd.